2023 Fiscal Year Final Research Report
Development of a Tumor-Selective Therapy Using Photo-Responsive Angiogenesis Inhibitors
| Project/Area Number |
20K22824
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0901:Oncology and related fields
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-09-11 – 2024-03-31
|
| Keywords | 光免疫療法 / VEGFR-2 / Minマウス / 大腸癌 / 蛍光内視鏡 |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to evaluate the efficacy of a newly developed photoimmunotherapy (PIT) targeting tumor endothelial cells in spontaneously developed colorectal cancer in ApcMin/+ mice. The study utilizes a photosensitive antibody compound (DC101-IR700) targeting VEGFR-2, expressed on the endothelial cells. The fluorescence accumulation in the tumor was confirmed via endoscopy following the administration of the compound. Subsequent exposure of the tumor to near-infrared light initiated the PIT process. A significant antitumor effect was observed when compared to untreated controls.
After treatment, pathological examination revealed the disappearance of cancer cells, infiltration of inflammatory cells, and fibrinoid necrosis of the vascular endothelium. These findings confirmed that the antitumor effects were mediated through vascular endothelial injury within the tumor.
|
| Free Research Field |
腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
腫瘍内血管内皮のVEGFR-2を標的とする新しい光免疫療法（NIR-PIT）がマウス大腸がんの治療として有効であることを証明した。従来の皮下移植モデルとは違い、自然発がんするマウス大腸がんモデルを用いた実験で効果を証明したため、人へ臨床応用しやすいことが期待される。この治療は正常細胞は傷害しないため従来のがん治療法に比べて副作用が少なく、より腫瘍選択的で効果的な大腸がん治療法の確立に寄与する可能性がある。これにより、患者の生存率の向上、及び生活の質の改善が期待される。
|
